TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Symptom response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differentially methylated CpG loci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: composite end point of death, reinfarction and class IV CHF
Endpoint domain: Mortality/survival
Primary endpoint: development of angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Treatment discontinuation rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Atrial fibrillation burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: composite of acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes
Endpoint domain: Mortality/survival
Primary endpoint: composite serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of health-associated commensal species in supragingival plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratings of meaningfulness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean decrease from baseline on the NPI agitation subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease from baseline in the diazepam-equivalent dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in psoriatic plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gadolinium enhancement as an indicator for inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BML (Body Mass Loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pure tone air conduction thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DPOAE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of blood loss for ABG measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: time to obtain ABG results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biochemical or clinical failure-free rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of grade 3 acute bowel toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of grade 3 acute bladder toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of histological or clinical stage 3-4 acute intestinal GvHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive and psychomotor performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sleep efficiency and sleep per cent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior Chamber Depth (ACD) stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nausea relief scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased phagocytosis and killing of neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increased superoxide production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of G‐CSF administration (no side effects leading to treatment discontinuation)
Endpoint domain: Adverse events/effects
Primary endpoint: dyadic adjustment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: intimacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sexual activity maintenance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Responder rates for sitting diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Control rates for sitting BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: negative beliefs about others
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: paranoia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of C. trachomatis diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Urinary sodium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative visual analog scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose-lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in mean common and maximum IMT of carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diet quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of nosocomial infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: maternal anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: infant prematurity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: low birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary protein excretion decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: maximal oxygen uptake (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to complete a 10 km cycling time trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tympanic temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of lung infiltrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of hepatosplenic candidiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average length of stay in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: NYHA Functional Classification (NYHA-FC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean reduction in plasma HIV-1 RNA copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of demands for analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume delivered via PCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provision of reassurance to women
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serious adverse events of infections
Endpoint domain: Adverse events/effects
Primary endpoint: number of analgesic boluses demanded per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of analgesic boluses delivered per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak flow measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cumulative vasopressor doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Umbilical arterial and venous blood pH and base excess
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vessel and tumor attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective image quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Selective attention improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Balance improvement (UBS and TUG scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Parent behavior change
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction of bacterial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: time necessary to recover renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: number of dialysis sessions required before recovery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Performance of fecal occult blood test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful primary hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: sodium fluorescein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early CPAP adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of composite responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained response over 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dietary consumption (fiber, fruit, vegetable, vegetable juice)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased perception of rest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced supplemental analgesics requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Blood product transfusions
Endpoint domain: Adverse events/effects
Primary endpoint: Decreased hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Excess Weight Loss (%EWL) at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response rate for weight loss dichotomized at 25%EWL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Repeat ED visits at 30 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Primary care visits at 30 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Usage of weight management program at 180 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AP index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non-severe hypoglycaemic events frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tiredness/fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reduced alertness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Plasma alitretinoin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myocardial oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants examined at year one
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Office visit with a nephrologist
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Urine microalbumin testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of BM B cell precursors (BCP CD34(+)/CD19(+)/CD10(+) cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of BM CD117(+) cells in CD34(+) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 10-year cumulated rate of permanent colostomy
Endpoint domain: Adverse events/effects
Primary endpoint: Overall balance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sway velocity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep onset latency (SOL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: graft resorption rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attenuation of endocrine counterregulatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Symptomatic counterregulatory response ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Labetalol concentration (AUC/dose x 1000)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: prevalence of breast tenderness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: bond failure rate
Endpoint domain: Mortality/survival
Primary endpoint: PDA (Percentage of Days Abstinent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: %HDD (Percentage of Heavy Drinking Days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary assisted patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Secondary patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Thickness of submucosal nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of heterotopic ganglion cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rightward shifts of the angiotensin II blood pressure response curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: annualized risk of stroke or non-CNS systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Thirty-day mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: Free fatty acids concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ketone bodies concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cost per life-year gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: sport/recreation function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Urinary L-FABP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new Q-wave appearance in electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute coronary syndrome events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Initial SN identification rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of false‐negative LM/SNB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication rate after LM/SNB
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of death or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: rate of repeated target-vessel revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of subjects achieving none or mild severity at maximum smile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average VAS pain score at 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of afebrile children after 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic improvement at 6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gains in clinical attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean defect resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor function of the paretic arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADL score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: maximal oscillation of muscle relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ETDRS Visual Acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical metamorphopsia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary anatomic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Abnormal laboratory test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal incisal range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: condylar range of motion in retrusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: Complete disappearance of the cystic portion of the thyroid nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence on follow-up ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WIC fruit/vegetable sales increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Ventriculo-arterial coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in global LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Complete Response (CR) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed to Expected Mortality Ratio (O/E)
Endpoint domain: Mortality/survival
Primary endpoint: Incremental rise in serum K(1) > 10 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall satisfaction with simulation realism
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gains in recognition/decision from simulation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in central retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients gaining 15 letters or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of serious hyperkalaemia (K(+) ≥6.0mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Electrolyte outcomes
Primary endpoint: significant renal dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: percentage of pelvic inflammatory disease symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: renal event-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: beta-cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: I‐VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICIQ‐UI‐SF score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24‐hour pad test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative prevalence of chronic neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete resolution of vasculitic neuropathy within 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean costs per person
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incident Congestive Heart Failure (CHF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity to carbachol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Progression of coronary artery aneurysm (CAA) size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of color defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative sensitivity of IDEIA PCE chlamydia test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Isoflurane requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes